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Background: Wolfram, Alström and Bardet-Biedl (WABB) syndromes are rare diseases with overlapping features of
multiple sensory and metabolic impairments, including diabetes mellitus, which have caused diagnostic confusion.
There are as yet no specific treatments available, little or no access to well characterized cohorts of patients, and
limited information on the natural history of the diseases. We aim to establish a Europe-wide registry for these
diseases to inform patient care and research.
Methods: EURO-WABB is an international multicenter large-scale observational study capturing longitudinal clinical
and outcome data for patients with WABB diagnoses. Three hundred participants will be recruited over 3 years
from different sites throughout Europe. Comprehensive clinical, genetic and patient experience data will be collated
into an anonymized disease registry. Data collection will be web-based, and forms part of the project’s Virtual
Research and Information Environment (VRIE). Participants who haven’t undergone genetic diagnostic testing for
their condition will be able to do so via the project.
Conclusions: The registry data will be used to increase the understanding of the natural history of WABB diseases,
to serve as an evidence base for clinical management, and to aid the identification of opportunities for intervention
to stop or delay the progress of the disease. The detailed clinical characterisation will allow inclusion of patients
into studies of novel treatment interventions, including targeted interventions in small scale open label studies;
and enrolment into multi-national clinical trials. The registry will also support wider access to genetic testing,
and encourage international collaborations for patient benefit.
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Wolfram, Alström and Bardet-Biedl (WABB) syndromes
are rare, monogenic, autosomal recessive disorders. They
are chronically debilitating, highly complex, and in com-
mon with other rare diseases, often subject to misdiagnosis,
delayed diagnosis, and non-diagnosis. The syndromes ex-
hibit clinical overlap: all can cause blindness, deafness, and
diabetes mellitus or impaired glucose tolerance. With 0.57,
0.14 and 0.8 cases per 100,000 [1] respectively, all three* Correspondence: T.G.Barrett@bham.ac.uk
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reproduction in any medium, provided the orWABB syndromes also fall within the EU rare disease def-
inition of ‘a prevalence of not more than 5 affected persons
per 10,000 population’ [2].
WABB diseases therefore form part of the estimated
5,000 – 8,000 recognized rare diseases in the EU, span-
ning a range of clinical specialties, and affecting an esti-
mated 29 million people [3]. Recommendations issued
by the European Council in 2009 highlight the need for
coordination and cooperation, and networking of re-
sources throughout Europe [4]. A number of projects in-
cluding Orphanet, EUROPLAN and EURORDIS have
made progress in this field. By building on the existing
generic frameworks and platforms for rare diseases,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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support efficient diagnosis, treatment, and research for
WABB diseases in Europe.
Wolfram syndrome
Wolfram syndrome (OMIM 222300) is characterized by
young onset diabetes and bilateral optic atrophy. It is
also known as the DIDMOAD, for the other features
of the disease including diabetes insipidus, diabetes
mellitus, optic atrophy, and deafness. Its prevalence was
estimated at 1 in 770,000 in the United Kingdom [5]. In-
sulin dependent diabetes usually occurs as the initial
manifestation during the first decade of life, with onset
of the other features in the second and ensuing decades
[6]. Neuroradiological examinations show widespread
neurodegeneration with severe brainstem atrophy [7,8].
The causative gene, WFS1 encodes Wolframin, a trans-
membrane protein located in the endoplasmic reticulum
(ER) [9-11]. WFS1 serves as an ER calcium channel and
has an important function in maintaining homeostasis of
the ER in pancreatic β-cells. More than 120 mutations in
WFS1 have been identified in patients and most of them
are inactivating (nonsense or frameshift) mutations.
Fairly recently, it has become evident that the transmis-
sion mode of disease-associated WFS1 mutations may
behave either dominantly or recessively and that the on-
set of medical symptoms may vary tremendously in age
of appearance and in degree of severity [12].
Alström syndrome
Alström syndrome (ALMS) (OMIM 203800) is charac-
terized by early onset blindness and obesity [13]. In
addition to the blindness, deafness, obesity and insulin
resistance originally described, cardiomyopathy, hyper-
lipidaemia, renal failure and hepatic fibrosis have been
reported [14-19]. The syndrome is caused by loss of
function mutations in ALMS1, encoding a protein of un-
known function located in basal bodies and connected
with ciliary function [20-22]. Alstrom patients, in con-
trast to many patients with Bardet Biedl syndrome, had
mostly normal intelligence and absence of polydactyly.
The condition is first apparent as photophobia and
nystagmus, leading to progressive visual loss from child-
hood. Obesity, insulin resistance, and partial nerve deaf-
ness follow, then type 2 diabetes (80%), severely high
blood triglycerides [19], cardiomyopathy (50%), with
more than 25% affected in infancy, and renal failure [18].
A smaller number also develop dyssynergy of the blad-
der resulting in incontinence. Some adult patients de-
velop skeletal abnormalities.
Bardet-Biedl syndrome
Bardet-Biedl syndrome (BBS) (OMIM 209900) is charac-
terized by early onset retinal dystrophy, obesity, andfrequent polydactyly [23]. Associated features can in-
clude childhood onset blindness, cystic kidneys, renal
failure, global learning difficulties, urological problems,
and neurological deficits including sensorineural deaf-
ness. Insulin resistance is common and Type 2 diabetes
usually develops from puberty onwards. One third of pa-
tients will develop renal failure and about 10% will pro-
gress to end-stage renal failure requiring dialysis and/or
transplantation. There are currently 17 genes associated
with BBS [24]. This genetic heterogeneity means that it
is not possible to distinguish causative genes based on
clinical grounds alone.
Other syndromes
There remain some rarer syndromes for which diabetes
mellitus is a significant part. These include Thiamine re-
sponsive megaloblastic anaemia syndrome (TRMA) (also
known as Rogers syndrome) and Wolcott-Rallison syn-
drome. Both are early onset, rare autosomal recessive
disorders. TRMA (OMIM 249270) is characterized by
Megaloblastic anaemia, diabetes mellitus and sensori-
neural deafness and Wolcott-Rallison (OMIM 226980) by
insulin-dependent diabetes occurring during neonatal and
early infancy [25,26]. The registry will capture information
about these cases alongside the WABB syndromes.
EURO-WABB research group
The EURO-WABB research project is managed by a col-
laboration of European scientists, clinicians and patient
group representatives. Project activities are overseen by
the Project Management Committee (PMC), with fur-
ther guidance from the Scientific Advisory Committee
(SAC). The project is supported by a number of collab-
orating partners, spanning a range of different stake-
holders, and also benefits from the insight provided by
Alström Syndrome UK Patient Support Group and the
French Wolfram Association.
The study objectives are as follows:
1. Establishing the natural history of WABB diseases.
Registry data will be used to better define disease
characteristics and outcomes. Specifically, the study
aims to identify whether the natural history varies
between population groups and how it changes over
time. This information will be used to ascertain
whether it is possible to predict from the natural
history of these diseases, groups of affected individuals
with different outcomes, and also stages during their
disease when they may be amenable to intervention.
2. Assessment of clinical effectiveness of management
and quality of care.
Assessment of clinical effectiveness of management
and quality of care. It is likely that there are It is
likely that there are disparities in the health care
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syndromes within the EU Member States.
Reassessment of existing and potential patients will
be used to refine the agreed diagnostic criteria and
to facilitate the development of consensus referral,
care and management pathways. This will include
the identification of requisite service components for
optimal disease management along with the
associated indicative costs. Given that it is likely that
assessment of clinical effectiveness will identify
knowledge gaps or specific learning needs of
healthcare professionals, educational materials and
training tools will be produced and disseminated to
target groups.
3. Development of a European cohort.
Research into rare diseases such as Wolfram,
Alström and Bardet-Biedl is limited by the lack of a
patient population of sufficient size from which to
develop an evidence-base. Seeking to achieve
Europe-wide collaboration, the EURO-WABB
registry will provide a large-scale source of
observational data to facilitate aetiological research
and to support the identification of sub-populations
for future interventional research.
4. Genotype-phenotype correlations.
The study will investigate whether the genetic
mutation can predict the natural history of the
disease and, in turn, whether this genetic diagnosis
can be used to predict an individual patient
outcome. Genotypic differences between WABB
patients with an identified mutation and those
presenting with a partial form phenotype will also be
assessed. To support these activities, the registry will
be linked to an open access, comprehensive
mutation database stored and catalogued using the
Leiden Open source Variation Database (LOVD)
web-database software package [27]. The database
lists all known pathogenic mutations (published and
unpublished) and is updated as new mutations are
identified. We also have included on the consent
form, the facility to collect tissue samples including
blood for RNA extraction. This will aid the
interpretation of mutations through assessment of
their function at the RNA level.
5. Increased and Equal Access to Genetic Diagnostic
Testing.
For participants who haven’t undergone genetic
testing to confirm diagnosis, and where the cost of
genetic testing is not met by national health funding,
this will be provided through the project. Access to
diagnostic testing will be via clinician referral,
ensuring that any resulting diagnosis is coupled with
appropriate counseling. Testing is provided through
a series of nationally accredited European diagnosticlaboratories and follows the pan-European approach
outlined in the recommendations by the European
Society of Human Genetics Public and Professional
Policy Committee (ESHG PPPC) [28,29]. Nine
laboratories currently undertaking diagnostic testing
for WABB diseases, and who are willing and able to
support this aim, have been identified. With their
expertise, and supported by project funding, Euro-
WABB aims to offer equal access to testing across
Europe. As a consequence, this may also lead to the
identification of novel mutations, particularly in
geographical populations who haven’t previously
been able to access testing.EURO-WABB project
Euro-WABB is a multi-centre observational study. A com-
prehensive anonymous registry of children and adults di-
agnosed with Wolfram, Alström, Bardet-Biedl or other
rarer diabetes syndromes from EU Member States will be
compiled. Registry data will be split between a ‘Core’
(minimum), ‘Extended’ and ‘Patient Experience’ datasets
(Additional file 1). The core dataset includes 44 variables,
consisting of summary current clinical and demographic
data, and capturing the clinical and genetic data necessary
to establish diagnosis. A further 370 variables capturing
detailed phenotypic data are included in the extended
dataset recording disease progression and date of onset of
symptoms form the extended dataset. Patient experience
data will record the patient’s journey and their experiences
from onset of symptoms, through diagnosis and the subse-
quent management of their condition (Figure 1).
Clinical diagnostic data across datasets will be
standardised using the International Classification of Dis-
eases (ICD) coding system (version 10). The endocrine
and hormone sub-set data will be further classified using
the European Society for Paediatric Endocrinology (ESPE)
Classification of Paediatric Endocrine Diseases.
Data records will be catalogued using a unique identi-
fier, with only the clinician caring for the participant able
to link the data record to his/her patient. Electronic data
validation systems will ensure that data sets conform to
the agreed data models and the quality and adequacy of
the submitted data will be regularly reviewed from a
clinical perspective. Housed within the overarching
VRIE, the database will offer secure access to, and shar-
ing of, data at local, national, and EU level. Access rights
and user privileges are determined by role/attribute con-
trol based models, with clinical partners and patient
partners contributing data to the data record.
Participants
A minimum of 100 subjects for each WABB disease,
plus 50 subjects with a diagnosis of Wolcott-Rallison
syndrome or Thiamine Responsive Megaloblastic Anaemia
Figure 1 Cartoon of the Euro-WABB registry project.
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The study sample will include both adults and children,
with no upper or lower age limits for data subjects. The
clinician caring for the patient will need to confirm eligi-
bility and written informed consent will be obtained prior
to registration for all participants. Eligibility is diagnosis
driven, with any individual with a clinical diagnosis of
WABB or other rarer diabetes syndrome eligible to take
part. This eligibility is further widened to include patients
who have an identified mutation in a W/A/BB gene(s) but
who may not exhibit the described phenotype for the asso-
ciated syndrome.
Data collection
The registry database is web-based and clinicians or del-
egated site staff will enter clinical registry data using a
browser-based form. The core and patient experience
datasets will be completed once, with the extended
dataset completed at repeating intervals generating com-
prehensive longitudinal data. Affected people or their le-
gally responsible carers will also be able to view and
enter data into the registry, provided that their core data
is first validated by their clinician (Figure 2).
Data analysis
The core and extended datasets will include demograph-
ics, family history, details of diagnosis, eye signs, deaf-
ness, diabetes, associated symptoms, quality of life and
investigations. A descriptive analysis of all variables willbe carried out first to determine the nature of variable
distribution. Each study participant will be categorized
where known by core diagnosis (Wolfram, Alström,
Bardet-Biedl, other) and then by genotypes (for instance
nonsense mutations, missense mutations). Phenotypic
information will include the age of onset of diabetes
mellitus, optic atrophy, deafness, renal or cardiac com-
plications; and longitudinal data entries on progression
of disease as to new onset of symptoms that were not
present at baseline data entry. From a biostatistical per-
spective, the phenotypic information falls into three
groups: – continuous, categorical (binary), or the time to
event. The data analyses include the unadjusted and ad-
justed comparisons of the clinical characteristics among
the genotype groups. In adjusted analysis, the investiga-
tors will quantify the effect of genotype on clinical char-
acteristics after controlling for potential confounders.
For continuous data, we will use the age of onset as an
example for description of analyses. A simple ANOVA
will be used to compare the means of age onset among
the genotypic groups for unadjusted analysis. For binary
data (Yes/No), the Chi-square test will be used to com-
pare the proportion of a particular characteristic among
the genotype groups.
For the time to event data, a Kaplan Meier time-to-
event curve will be generated for each genotype group
with the logrank test for statistical significance. The ad-
justed analysis will be performed using the Cox Propor-
tional Hazard Model.
Figure 2 Data fields held in the registry.
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The study was granted ethical approval by The National
Research Ethics Service West Midlands Committee –
Staffordshire, REC reference 11/WM/0127 in August
2010, and a substantial amendment approved on 22nd
January 2013.
Recruitment of vulnerable groups
The sample population includes a number of vulnerable
groups, including adults lacking capacity to give consent,
minors and those with special communication needs, e.
g. those with a visual or hearing impairment. Detailed
participant information will be provided, in a variety of
formats, and where appropriate the potential partici-
pant’s parent, legal guardian or a consultee will be in-
cluded in the information giving and consent seeking
processes. Additionally, given that WABB syndromes
may significantly shorten life expectancy, it may also be
appropriate to collect data relating to deceased patients.
This will be subject to consent from the deceased per-
son’s next of kin, and only where the clinician feels that
this will not be unduly distressing to the deceased per-
son’s family.
Summary
A common core dataset for European Union states has
been developed that can be shared between national raredisease registries as they are established; and will allow
linkage with other international disease registries. Agree-
ment on this core dataset for WABB and other very rare
diabetes syndromes is essential in order to compare data
between national registries, link registries and to identify
subgroups of patients that may be eligible for clinical tri-
als or to prioritise genes for mutation searches.
Achieving true Europe-wide collaboration may prove
challenging. High usage of the registry will be achieved by
linking it to rapid genetic testing; and to up to date, accur-
ate information, FAQS, and education material. Additional
awareness raising activities such as dissemination of
promotional materials and the development of a multi-
language project website (www.euro-wabb.org) and dis-
semination of promotional materials will also be under-
taken to help to overcome this challenge.
To encourage maximum participation by health pro-
fessionals, and in recognition that not all partners will
want others to see anonymised clinical data on their
own patients, we have included an option to restrict ac-
cess to their own data. We sincerely hope that most clin-
ical partners will allow their anonymised data to be
shared with bona fide researchers working on approved
study protocols. Any group of researchers or a pharma-
ceutical company can apply to the Project Steering
Group for access to data in the registry to investigate
one or more of these diseases. If permission is granted,
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whom the clinical partner has granted permission to
share data. The data can be restricted to one particular
rare disease, to the core datasets, or to system specific
data for instance endocrine, cardiac or genetic data.
There are some existing registries for these diseases,
based in North America. There are also subspecialty
specific databases, that have good penetration with
certain groups of health professionals. Euro-WABB has
good penetration with endocrinologists, diabetologists
and geneticists. There are other registries, such as for
deafness, that may also include affected patients with
these conditions. In addition, some patient groups set
up their own disease registry. Pharmaceutical compan-
ies may develop a disease specific registry to deter-
mine natural history and monitor outcomes of novel
treatments. There may be a case for a specific rare
disease to be included in more than one registry, in
order to maximize penetration among different inter-
est groups. Given the ultra-rare nature of these dis-
eases, it is important that all anonymised data is
shared for maximum patient benefit. To this end we
have included on the consent forms, specific consents
to allow sharing of data with national, European, and
other international disease registries. It is hoped that
use of the ICD10 codes, will support shared definitions
of symptoms to allow comparison and pooling of data
between registries.
It is also recognized that there will need to be more
than one entry route to achieve maximum participation
in this European registry. Some affected families will re-
search their own condition through internet search en-
gines and find the European registry. We have therefore
incorporated a route to allow patients to self register
and submit core data and quality of life data about
themselves. By asking for contact details for their local
doctor, we hope to be able to approach that person to
invite to participate as a clinical partner.
We believe in principle that patients should be able to
see what data is held on themselves, but not other pa-
tients, electronically. We have consulted widely with pa-
tient groups and therefore have incorporated a secure
system to allow patients to see their own core data on-
line. The extended dataset includes data that is more
complex, and may require some explanation by the local
physician. We therefore encourage patients who would
like to see their own extended dataset, to approach their
local physician to view this.
In line with existing evidence and recommendations
highlighting that rare disease registries can lead to im-
proved recognition, correct diagnosis, and earlier treat-
ment for patients [30,31], it is hoped that Euro-WABB
will lead towards quality of life improvements through
earlier diagnosis, prompt identification and managementof complications. The registry will develop collaborative
links which will be the precursor to a European Refer-
ence Network for these diseases.
Additional file
Additional file 1: List of data fields in core and extended datasets.
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